On September 20, 2023, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (referred to as "Yuanda Shuyang"), a wholly-owned subsidiary of Grand Life Science Group Co., Ltd. (referred to as "Grand Life Science"), and Suzhou Alphamab Oncology Biotechnology Co., Ltd. (referred to as "Suzhou Alphamab Oncology"), jointly announced that both parties have entered into a collaboration agreement for the licensing of KN057, a Tissue Factor Pathway Inhibitor (TFPI) monoclonal antibody developed by Suzhou Alph

Recently, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Yuanda Shuyang Pharmaceutical" or "the company"), a subsidiary of Grand Life Science Group, has obtained a Certificate of Pharmaceutical Product issued by NMPA for its human coagulation factor products. Yuanda Shuyang Pharmaceutical's human coagulation factor IX (Shuyang Yinjiu) is about to be launched for sale.

On February 8, 2023, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Yuanda Shuyang"), a wholly-owned subsidiary of Grand Life Science Group, entered into a collaboration with GenScript ProBio on the project of recombinant coagulation factor V for injection (project code: GLS-C3512). GenScript ProBio will provide clinical sample production, process characterization, process validation research, BLA application, and commercial production services for Yuanda Shuyang.

On January 15, 2023, Sichuan Yuanda Shuyang Pharmaceutical held its 2022 annual summary and commendation conference with the theme of "Developing by War, Strengthening Shuyang". Pan Wenqing, General Manager of the Group's Operation and Management Headquarters, Feng Zenghui, Chairman of the Grand Life Sciences Group and Chairman of Yuanda Shuyang Pharmaceutical, Zhou Lujin, Vice President of the Grand Life Sciences Group and General Manager of Yuanda Shuyang Pharmaceutical, and a number of leader

Recently, Yuanda Shuyang’s new production base achieved the first export of Human Immunoglobulin for Intravenous Injection (hereinafter referred to as "IVIG") to South American countries. As a leading exporter of blood products in China, Yuanda Shuyang has been deeply cultivating the international market over 20 years, with its products being sold to more than 10 countries and regions in Asia, Eastern Europe, the Middle East, Latin America, etc. 

Recently, Sichuan Yuanda Shuyang Pharmaceutical, a wholly-owned subsidiary of Grand Life Science Group, has entered into an exclusive license agreement with Neoletix (Beijing), under which Sichuan Yuanda Shuyang Pharmaceutical will be granted an exclusive right to develop, register, and commercialize human recombinant factor VIII (project code: NX01) in the Greater China region.

Organized by the China International Exchange and Promotive Association for Medical and Health Care (CPAM) and the Renal Transplantation Branch of CPAM, and hosted by West China Hospital of Sichuan University, the 2022 Academic Annual Conference of Renal Transplantation Branch of CPAM and the 6th Huaxia Renal Transplantation Forum were held on July 15-17, 2022 in Chengdu City. There were more than 5,000 participants in this conference offline and online. Yuanda Shuyang Pharmaceutical participate